Checkpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial Design May Explain ...

A phase 1 trial of relatlimab plus nivolumab in recurrent glioblastoma reveals that checkpoint inhibitor failure in brain tumours stems not from drug mechanism but from trial design architecture; the trial's protocol innovations—parallel cohorts, systematic neurological monitoring, pre-specified imaging windows—establish a replicable template for detecting efficacy signals in immunosuppressive CNS environments.

This Wire brief sits within Fusion42's coverage of Biotech, Drug Discovery and Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.